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Pathogenesis and host ResPonse
Background: Clostridium difficile is capable of causing severe enterocol-
itis in adults. The significance of toxin-producing C. difficile in children 
with diarrhea is unclear and practice differs on whether to institute treat-
ment. We aimed to characterize the microbiome in relation to the presence 
of C. difficile and co-infection with other pathogens and to describe host 
response to infection.
Methods: Participants were children with acute diarrhea, 0–16 years of age, 
from whom stool samples had been submitted to the hospital laboratory 
for routine microbiology/virology. Convenience sampling was used for 50 
prospective and 150 retrospective samples. No participants were treated for 
C. difficile. Rates of culture positivity for C. difficile, presence of toxin and 
PCR-ribotype were compared between age groups. Presence of other poten-
tial pathogens, comorbidities and complications were recorded. Microbiotal 
diversity was measured by 16S profiling.
Results: Nineteen of 77 (25%) children <2 years of age and 13 of 119 
(11%) children >2 years of age were C. difficile positive, of whom 10 (53%) 
and 9 (69%), respectively, carried toxigenic strains. Increased Shannon 
diversity was seen in children carrying C. difficile, with altered milieu. Pres-
ence of C. difficile was not associated with adverse clinical outcomes. In 
stools containing both Norovirus and C. difficile, there was increased rela-
tive abundance of verrucomicrobia.
Conclusions: Children with diarrhea regularly carried toxigenic and non-
toxigenic strains of C. difficile, demonstrating enhanced microbiotal diver-
sity, and change in milieu, without apparent morbidity. This unexpected 
finding is contrary to that seen in adults with C. difficile disease.
Key Words: C. difficile, diarrhea, children, host response
(Pediatr Infect Dis J 2020;39:221–228)
Clostridium difficile (C. difficile); a Gram-positive, anaerobic, spore-forming bacillus, existing in both toxigenic and non-
toxigenic forms, is a significant cause of nosocomial infection and 
associated morbidity/mortality; particularly in the elderly follow-
ing the emergence of hypervirulent strains such as PCR ribotypes 
078 and NAP1/B1/027.1,2 Healthy neonates and infants frequently 
carry C. difficile (including toxin-producing strains), as part of 
their bowel flora, without apparent adverse effects. The mecha-
nisms by which this occurs remain obscure, with immaturity of 
receptors for C. difficile toxin in the infantile gut3 or a protective 
effect of breast milk via transfer of neutralizing antibodies to tox-
ins A and B postulated as major contributors.4,5 C. difficile infec-
tion (CDI) requires alteration of the colonic flora, colonization 
by toxigenic C. difficile and release of enterotoxins (Toxin A and/
or Toxin B) for disease establishment. Broad-spectrum antibiotic 
therapy eliminates intestinal commensals, allowing overgrowth of 
C. difficile and potential CDI. It has been reported that relapse/
recurrence of CDI in adults occurs in those with low levels of IgG/
IgM to C. difficile toxins.6 Seropositivity rates increase with age, 
with 11% and 33% of infants <6 months of age displaying antibod-
ies to Toxin A and B, respectively, increasing to 25% and >50% 
seropositivity by 2 years of age.7
Asymptomatic C. difficile carriage decreases with increas-
ing age; up to 70% carriage has been reported in healthy neonates,3 
falling to around 10% at 1 year, and reaching comparable rates with 
adult colonization of 4% by 2 years. Despite a global decrease in 
CDI rates, incidence appears to be increasing amongst traditionally 
“low risk” groups for infection, such as children and adults in the 
community.8 There have also been more cases in hospitalized chil-
dren with known “risk factors” for infection, such as hematologic 
malignancies, inflammatory bowel disease and antimicrobial use.9 
Rising reported rates of CDI10 may be partially due to the intro-
duction of more sensitive nucleic acid amplification-based testing. 
C. difficile is currently on the Center for Disease Control’s list of 
“urgent threats” to US public health.11
The gut microbiome is frequently less diverse in adult 
patients with CDI.12–14 The pediatric gut microbiome is influ-
enced by numerous factors, including gestation, mode of delivery 
at birth, method of feeding, medications and environmental fac-
tors, but whether the presence of C. difficile also influences this 
remains unclear. Broad groups of bacteria are largely similar across 
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individuals, but there is a great degree of diversity and individuality 
in the acquisition of species over time.15
C. difficile is often treated as a pathogen in children with diar-
rhea, particularly in the United States,16 but this may be unnecessary. 
In hospitalized children with diarrhea and C. difficile in their stool, 
we aimed to characterize the microbiome in relation to co-infection 
with other pathogens and to describe host response to infection.
PATIENTS AND METHODS
Setting
Alder Hey Children’s NHS Foundation Trust Hospital is a 
university-affiliated pediatric teaching hospital in the north-west of 
England, undertaking >275,000 patient care episodes per annum.17 
We recruited children 0–16 years of age experiencing acute diar-
rhea, with samples submitted for microbiologic testing at the 
request of medical staff.
Prospective Study
Fifty stool samples sent for stool microbiology/virology 
testing were collected between November 2013 and January 2014 
from inpatient diarrheal specimens. Samples with sufficient yield 
following routine testing were immediately stored at −70°C. If the 
child had undergone blood tests that day, any remaining plasma 
was stored at −20°C. Samples were anonymized after extraction of 
clinical data and analyzed at a later date.
Retrospective Study
One hundred and fifty stool samples from children with diar-
rhea submitted for stool microbiology/virology between January and 
July 2013 were collected. Samples were from hospitalized children 
and Emergency Department attendees. Four samples were found to be 
duplicates and removed from the study (ie, same patients on the same 
admission). C. difficile testing is not routinely done on these samples. 
None of the children were treated for CDI (see Figure, Supplemental 
Digital Content 1, http://links.lww.com/INF/D729, for sample flow).
Patient demographics and data on comorbidities and medi-
cation use were obtained for both groups.
Ethical Statement
Study design was reviewed and approved by the NHS 
Research Ethics Committee London—Fulham (reference: 13/
LO/1495) and the Research and Development departments of 
Alder Hey Children’s NHS Foundation Trust and the University of 
Liverpool. Written informed consent was taken from parents of all 
participants in the prospective study and written assent from par-
ticipants, where age-appropriate.
Sample Analysis
Stool Culture and C. difficile Detection
All stool samples underwent alcohol-shock treatment, fol-
lowed by culture for C. difficile on Brazier’s cefoxitin-cycloserine 
egg yolk agar as previously described.18 Samples underwent lateral 
flow testing for the presence of C. difficile glutamate dehydroge-
nase and the presence of toxins A and/or B with C. diff Quik Chek 
Complete (Alere LTD, Stockport, United Kingdom), following 
manufacturers’ instructions.
Fecal Cytokines
Stool supernatants from 72 samples; 30 C. difficile-positive 
(with sufficient remaining sample) and 42 C. difficile-negative sam-
ples (aged within 1 year of positives) underwent testing for fecal 
cytokine levels with the V-PLEX Pro-inflammatory panel 1 (Meso 
Scale Discovery, Rockville, MD). Briefly, 50 μl/0.05g stool were 
suspended in 250 μl PBS/Sigmafast protease inhibitor (Sigma-
Aldrich Ltd, Dorset, United Kingdom), and following vortexing 
and centrifugation, the resulting supernatant was utilized in the kit 
as per manufacturers’ instructions.
Molecular Methods
PCR assays for toxin genes, ribotyping, 16S parallel 
sequencing and testing for additional pathogens using the Luminex 
Gastrointestinal pathogen panel (GPP) were completed on 59 sam-
ples. Methods and sample selection procedure are described in 
detail in online Appendix 1.
Statistical Analysis
All results were analyzed using STATA (release 14·0, 
STATA Corp., College Station, TX) or GraphPad Prism (release 
7·0a, GraphPad Software Inc., La Jolla, CA). Data which were par-
ametrically distributed were examined with t test, while Kruskal-
Wallace/Dunn test was employed for non-parametrically distributed 
data, with a P value <0.05 considered significant. See Supplemen-
tal Digital Content 2, http://links.lww.com/INF/D730 for statistical 
methods for 16S data.
RESULTS
Demographics and Patient Characteristics
Participants ranged from 0 to 16 years of age (Median 3·0; 
IQR 0.83–9); 77 (40%) were <2 years of age, and 119 (60%) ≥2 
years of age. Of the 32 samples testing positive for C. difficile, 21 
(64%) were sent within 72 hours of admission (see Tables 1 and 2 
for further patient demographics by group). C. difficile positivity 
was not associated with increased length of stay.
TABLE 1. Population Demographics by Group (<2 Years)
Culture negative  
(CN) (n = 58)
Non-toxigenic carriers  
(NTC) (n = 9)
Toxigenic carriers  
(TC) (n = 10) P (Dunn test)
Age (months) 5.52 (IQR 2.04–12.48) 8.99 (IQR 8.52–15.96) 12 (IQR 7.80–14.28) 0.03 (CN vs. NTC),  
0.008 (CN vs. NTC/TC)
Sex (male) 29/58 (50%) 7/9 (78%) 4/10 (40%) NS
Length of stay (days) 8.5 (IQR 1.75–43) 2 (IQR 0–6.5) 6.5 (IQR 2–25.75) 0.03 (CN vs. NTC)
Time to sample (days) 3 (IQR 1–18.5) 1 (IQR 0–2) 2 (IQR 0–8.5) 0.01 (CN vs. NTC)
Comorbidities* 38/75 (51%) 5/9 (56%) 6/10 (60%) NS
Current antibiotics 14/68 (21%) 4/7 (57%) 4/8 (50%) 0.04 (CN vs. NTC),  
0.07 (CN vs. TC)
Antibiotics past 3 months 34/58 (59%) 6/6 (100%) 4/5 (80%) 0.05 (CN vs. NTC)
Current PPI/H2RA 18/68 (26%) 2/7 (29%) 3/8 (38%) NS
Currently PEG/JEJ fed 16/71 (23%) 3/9 (33%) 3/9 (33%) NS
*Comorbidities considered were diagnoses in the following categories: hematologic, neurologic, gastrointestinal, respiratory, cardiologic and other.
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In the <2-year group, 19 (25%) samples tested positive for 
C. difficile (defined as positive result on both culture and lateral 
flow testing), of which 10 (53%) were toxigenic strains. In the 
>2-year group, 13 (11%) samples tested positive for C. difficile, of 
which 9 (69%) were toxigenic strains. PCR-ribotypes were more 
diverse in the >2-year olds, in whom 12 different strains were iden-
tified with only type 002 being detected twice. In contrast, 039 (9 
samples) and 020 (6 samples) were identified most frequently in the 
<2-year olds (Fig. 1A,B).
There was a significant difference in median age of those 
<2 years testing positive for C. difficile; 0.83 (IQR 0.67–1.25) 
versus 0.42 (IQR 0.17–1.04) years for those testing negative 
(P = 0.008). Male patients were significantly more likely to carry 
non-toxigenic C. difficile; 11 of 13 (85%) carriers were male versus 
87 of 164 (53%) culture negative (P = 0.01).
There was an association between comorbidity and carriage 
of toxigenic C. difficile in those >2 years; 63% (67/106) culture-
negative patients had comorbidities versus 100% (9/9) patients 
with a toxigenic strain (P = 0.03). All children over 2 years with 
C. difficile had a comorbidity, these included malignancy, cerebral 
palsy or other congenital syndromes causing multisystem disor-
ders. A significant proportion of culture-negative children >2 years 
(63%) also had a comorbidity; however, with a similar spread of 
conditions, as well as some children with gastrointestinal disorders.
Maximum C-reactive protein (CRP) was significantly 
higher in children carrying toxigenic C. difficile; CRP 10.1 (IQR 
4–61.8) in culture negative, 9.5 (IQR 4–52.2) in non-toxigenic and 
34.8 mg/L (IQR 4–144.4) in toxigenic carriers (P = 0.04) (Fig. 2). 
There was a non-significant association between toxigenic carriage 
and higher white cell count (WCC).
Recorded diagnoses for all participants were as follows: 
Unspecified loose stools 55 of 196 (28%), gastroenteritis (no 
reported organism) 19 of 196 (10%), gastroenteritis (organism 
identified) 12 of 196 (6%), upper/lower respiratory tract infection 
33 of 196 (17%), sepsis 13 of 196 (7%) and other 64 of 196 (33%).
Coinfections
Using the GPP panel, pathogens were identified in 27 of 59 
(46%) of the 59 stools tested, with norovirus being detected in 21 
of 59 (36%). C. difficile/norovirus co-infection occurred in 9 of 21 
(43%) of these cases (see Table, Supplemental Digital Content 3, 
http://links.lww.com/INF/D731).
Co-infection with virus, but not bacteria was associated with 
presence of C. difficile, (P = 0.001), and also the presence of a toxi-
genic strain (P = 0.004). There was no association between elevated 
WCC or CRP and presence of co-infection.
Fecal Host Response Biomarkers
Children with a diagnosis of inflammatory bowel disease 
had higher levels of both pro- and anti-inflammatory cytokines 
(TNFα, IL-4, IL-6, IL-8, IL-12, IL-1β, IL-13, IL-12p70, IL-10 
and IFNγ, all P < 0.0025). There was no clear pro-inflammatory 
response in those with C. difficile, versus those without, regard-
less of toxin status, with no significant difference noted in cytokine 
levels between groups.
16S Sequencing Results
Taxonomic data were available for 42 children; these were 
split into 3 groups for analysis: 18 culture negative, 9 carrying non-
toxigenic C. difficile and 15 carrying toxigenic C. difficile. Data 
were analyzed in terms of Shannon diversity index, which incorpo-
rates both richness of diversity (ie, number of species present) and 
their relative abundance. Chao1 and Species Abundance Coverage 
Estimator were also reported on, which are alternative methods of 
estimating true species diversity and abundance, respectively.
Shannon diversity index was higher among children who 
were culture positive [toxigenic or non-toxigenic (P < 0.05)], but 
Chao1 and Species Abundance Coverage Estimator species rich-
ness indices did not differ significantly across the 3 groups (Fig. 3).
At the phylum taxonomic level, culture negative and non-
toxigenic carriers of C. difficile demonstrated increased propor-
tions of Firmicutes and Bacteroidetes, with fewer Proteobacteria. In 
toxigenic C. difficile carriers, the converse was true, with a marked 
increase in abundance of Proteobacteria. In C. difficile and norovirus 
co-infection, there was a bloom in Verrucomicrobia; this was seen to 
a lesser degree in those with norovirus alone, but not witnessed in 
any other group. Those who were norovirus positive alone also dis-
played an increase in abundance of Proteobacteria with a concomi-
tant decrease in Actinobacteria. Conversely, Actinobacteria appeared 
to be more abundant in C. difficile-positive patients (Fig. 4; Figure, 
Supplemental Digital Content 4, http://links.lww.com/INF/D732).
Additionally, Lachnospiraceae and Ruminococcaceae fam-
ily abundance was significantly higher in those who were carrying 
either toxigenic or non-toxigenic C. difficile (P < 0.001 and P < 0.006, 
respectively). The genus Klebsiella was significantly more abun-
dant in carriers of toxigenic strains of C. difficile (P < 0.006).
The coverage depth of our sequencing data allowed the 
confirmation of C. difficile presence at very low levels (maximum 
relative abundance of 0.003%), and detected 2 further carriers who 
were negative on culture/lateral flow testing.
DISCUSSION
Key findings of this study were increased Shannon diversity 
index in C. difficile-positive children with diarrhea (particularly 
TABLE 2. Population Demographics by Group (>2 Years)
Culture negative 
(CN) (n = 106)
Non-toxigenic carriers  
(NTC) (n = 4)
Toxigenic carriers 
(TC) (n = 9) P (Dunn test)
Age (years) 8 (IQR 4.13–12) 8 (IQR 7–11.25) 4.42 (IQR 3.08–7.5) NS
Sex (male) 58/106 (55%) 4/4 (100%) 1/9 (11%) 0.08 (CN vs. NTC) 0.01  
(CN vs. TC), 0.003 (NTC vs. TC)
Length of stay (days) 7 (IQR 0–20) 12 (IQR 3–46.5) 8 (IQR 4.5–129) NS
Time to sample (days) 1 (IQR 0–8.25) 4.5 (IQR 1.75–8.75) 3 (IQR 1.5–52.5) 0.04 (CN vs. NTC)
Comorbidities 67/106 (63%) 4/4 (100%) 9/9 (100%) 0.03 (CN vs. TC)
Current antibiotics 37/99 (37%) 2/4 (50%) 4/9 (44%) NS
Antibiotics past 3 months 59/60 (98%) 4/4 (100%) 7/8 (88%) NS
Current PPI/H2RA 32/99 (32%) 4/4 (100%) 6/9 (67%) 0.005 (CN vs. NTC),  
0.04 (CN vs. TC)
Current PEG/JEJ fed 26/104 (25%) 4/4 (100%) 5/9 (56%) 0.001 (CN vs. NTC),  
0.05 (CN vs. TC)
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non-toxigenic carriers), with change in milieu, and a Verrucomi-
crobial bloom in those co-infected with C. difficile/norovirus.
A study of gut microbiota in 53 healthy infants showed no 
decrease in global diversity with the presence of C. difficile, and 
similarly to our study, an increased abundance of Klebsiella and 
Ruminococci19 Findings in children contrast with those in adult C. 
difficile patients, in whom the diversity of the microbiota is dimin-
ished, with decreased abundance of Ruminococci reported.20,21 A 
high relative abundance of Lachnospiraceae has been suggested to 
be protective against C. difficile.22,23 This may reflect the fact that 
in adults, the cause of diarrheal disease was C. difficile, whereas 
this was not thought to be the case in our pediatric patients. None 
of the children in our study were treated for CDI. There is no clear 
reason why C. difficile does not appear to affect the diversity of 
the pediatric gut microbiome in the way that it does in adults; one 
explanation could be that the bacteria is preferentially existing in 
spore form in the pediatric gut, with conditions not being optimal 
for proliferation of the vegetative form.24 One longitudinal study 
of the microbiota of an asymptomatic infant covering periods of 
breast-feeding and weaning found carriage of 2 different strains 
of C. difficile over the study period at both high vegetative and 
spore counts, with presence of toxin levels that would be high 
enough to cause disease in adults. In this case, change in micro-
biotal composition associated with alteration of diet from breast 
milk to cow milk caused rapid expulsion of C. difficile from the 
bowel.25
Temporal and spatial overlap between norovirus outbreaks 
and CDI, which may be potentially synergistic, has been documented 
previously.26 Norovirus and C. difficile co-infection have been 
reported in other pediatric studies,27,28 but those with co-infections 
were clinically indistinguishable from those with C. difficile alone, 
despite the higher bacterial burden in co-infection. This suggests that 
Norovirus leads to a loss of colonization resistance to C. difficile, 
rather than a dysbiosis. Also noted during our study was that propor-
tions of Firmicutes and Bacteroidetes decrease and Proteobacteria 
increase in children with toxin-positive C. difficile. This raises the 
possibility that these differential abundances in the presence of toxin 
could drive disease, as opposed to the presence of C. difficile per se. 
FIGURE 1. Figures representing diversity 
of C. difficile strain isolated, investigation of 
systemic response and effect of C. difficile 
on microbiota. A: PCR-ribotypes identified 
in children <2 years old. B: PCR-ribotypes 
identified in children >2 years old. PCR-
ribotypes identified in children >2 years old 
were much more diverse than those detected 
in children <2 years old, suggesting sharing 
of strains between children <2 years old 
before toileting/hand hygiene habits are 
learnt. 
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Our data suggest C. difficile may be a bystander in diarrhea caused 
by other primary pathogens; supported by the finding of similar car-
rier frequency in the “healthy” outpatient population in a number of 
studies.29,30
The proportion of children who tested positive for C. dif-
ficile within 72 hours of admission fits with the current increase in 
cases of community-associated C. difficile being identified in adults 
and children in the United States.1,8,16 Prevalence of C. difficile in 
the age-stratified population studied here fit with those found in an 
extensive literature review.29
We only found an association between current antibiotic 
use and C. difficile carriage in the <2-year age group in this study; 
largely because of the very high prevalence of recent antibiotic use 
in both groups. More detailed information on class of antibiotic 
used would have been valuable to correlate with C. difficile status. 
Another factor of interest would be repeated sampling over time 
around a course of antibiotics to observe changes in microbiota 
associated with treatment.
A limitation of our study is that not all samples under-
went GPP panel testing or 16S sequencing. Given the retrospec-
tive nature of many of the samples, we were unable to determine 
whether all participants had been in contact with hospitals in the 
past 3 months, so the proportion with community-associated car-
riage may be overestimated.
The significantly higher CRP in those found to carry toxi-
genic C. difficile raises the question of whether CRP is elevated in 
relation to intestinal inflammation due to presence of C. difficile 
toxin, or whether systemic inflammation provides favorable condi-
tions for C. difficile colonization. A study on children with diar-
rhea following antibiotic use noted a significantly higher CRP in 
the group in whom toxigenic C. difficile was detected, with similar 
demographics between groups, although no data on outcome were 
available.31
It has been suggested that children could form a reservoir 
for infection in adults, with a higher prevalence of community-
acquired CDI in those adults who had contact with children <2 
years of age.32 A large UK study of CDI cases demonstrated that in 
those with fewer than 2 single nucleotide variants between infecting 
strains (consistent with transmission), 36% patients had no hospi-
tal/community contact with one another, suggesting an alternative 
reservoir in the community which could be pediatric.33 A follow-up 
study found 50% of C. difficile strains from healthy infants shared 
a common lineage with a local CDI case within the past 5 years.34 
We compared our data to unpublished data gathered from hospital-
ized adults in the same region and found a large degree of overlap 
FIGURE 2. Figures representing diversity 
of C. difficile strain isolated, investigation of 
systemic response and effect of C. difficile 
on microbiota. A: CRP by C. difficile status. 
Maximum CRP was significantly higher in 
children carrying toxigenic strains of C. difficile 
versus those with non-toxigenic strains and 
those who were culture negative (P = 0.04). 
Note: CRP defined as normal (<4), moderate 
(4–20), high (20–100) and very high (>100). 
B: WCC by C. difficile status. Those with 
toxigenic C. difficile had a higher WCC in 
but this was not significant. The increased 
prevalence of neutropenia in this group 
likely represents the fact that hematologic 
comorbidity was associated with toxigenic 
C. difficile carriage. Note: WCC defined 
as neutropenic (<1.5 × 109), normal (1.5–
15 × 109), high (15–20 × 109) and very high 
(>20 × 109). 
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in strains detected between these adults and children in our study, 
suggesting transmission of strains between children and adults in 
our region. In accordance with our findings in the <2-year group, 
ribotype 020 was also one of the most prevalent ribotypes found 
in large scale European and Korean studies of hospitalized adults 
and a Spanish study of children under 2 years.35–37 In a US study of 
hospitalized and community adult stool samples, 020 and 039 were 
found to be the third and fourth most prevalent ribotypes, respec-
tively.38
C. difficile PCR-ribotypes found in children >2 years of age 
in this study were much more diverse than in those <2 years, sug-
gesting that there is less sharing of strains once toileting and hand 
hygiene habits are learnt.
Infants and children with diarrhea regularly carry toxigenic 
strains of C. difficile without apparent adverse effects. None of the 
children in this study were diagnosed with or treated for CDI and 
although higher CRP was associated with toxigenic carriage, there 
was no increase in local inflammatory cytokine response, which 
has previously been used to predict disease severity.39 Interestingly, 
a recent pediatric study found specific but not sensitive elevation of 
phosphorylated-p38 in both healthy and diarrheal children with C. 
difficile. The only measure correlating with prolonged diarrhea in 
those with C. difficile was abundance of CXCL-5 mRNA. Bacterial 
burden did not differ between healthy and symptomatic children 
and did not correlate with clinical outcome.40 In our study, carriage 
conferred no morbidity in terms of length of hospital stay. Other 
studies have shown no difference in outcome in diarrheal children 
<2 years of age with toxigenic C. difficile in their stool who were 
treated, versus those left untreated.37
Further studies comparing age-matched healthy controls 
with or without C. difficile carriage versus those with diarrhea 
would provide further insight as to the significance of C. difficile in 
the pediatric bowel, and may contribute to the development of guid-
ance on which children require treatment. These results would be of 
particular relevance to practice in the United States where pediatric 
CDI is diagnosed more frequently and treated more aggressively.
FIGURE 3. Figures representing diversity 
of C. difficile strain isolated, investigation of 
systemic response and effect of C. difficile on 
microbiota. A: Shannon entropy by age. B: 
Shannon entropy by C. difficile status. Strip plot 
of Shannon entropy between groups, circles 
represent individual data points, box 25th–75th 
centile and whiskers 5th–95th centile. There 
was no difference in Shannon entropy between 
age groups, but entropy was significantly 
higher in those carrying C. difficile, regardless of 
toxin status. Note: *P < 0.05. 
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